"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

According to information from Zhihu Finance APP, vVardis Holding (VVVV.US), which sells proprietary non-invasive cavity treatment products, announced its IPO terms last Friday. This Zug, Switzerland-based company plans to issue 9.5 million shares at a price range of $21–$24, raising $214 million. At the midpoint of the price range, vVardis Holding is valued at approximately $1.3 billion.

vVardis develops and sells Curodont—a peptide-based early cavity treatment solution that can be administered in dental clinics in 5 minutes or less, without drilling or injections. Its U.S. product, Curodont Repair Fluoride Plus, is sold as an over-the-counter drug under the FDA monograph, contributing the majority of the company's revenue. A fluoride-free version, Curodont Repair, is marketed as a medical device in the UK and some parts of Europe. In the U.S., the company distributes exclusively through Henry Schein and is further supported by its own sales team.

vVardis Holding was established in 2020. For the 12 months ending June 30, 2026, its revenue reached $50 million. The company plans to list on the New York Stock Exchange under the ticker VVVV. Goldman Sachs, JPMorgan, William Blair, UBS Investment Bank, and Deutsche Bank are joint bookrunners for this transaction. Pricing is expected during the week of Monday, November 9, 2026.